Alpha-lipoic Acid Combined With B Vitamins Shows Promise for Treating Restless Legs Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-04

Study Completion Date

2021-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigating Tiobec® 400's efficacy in alleviating Restless Legs Syndrome symptoms sheds light on promising therapeutic avenues.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antioxidant Functions of Lipoic Acid

NCT00065624

Hypercholesterolemia

COMPLETED PHASE2

Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia

NCT04485793

Hypercholesterolemia

COMPLETED NA

Combined Effects of Bioactive Compounds in Lipid Profile

NCT01562080

Hyperlipidemia Low-density-lipoprotein-type Elevated Triglycerides

COMPLETED PHASE2/PHASE3

Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

NCT01391377

Peripheral Arterial Disease

TERMINATED NA

Effects of 10 mg Monacolins on Vascular Health: a Clinical Trial

NCT02492464

Atherosclerosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Restless legs syndrome, also known as Willis-Ekbom disease, is a neurological disorder characterised by uncomfortable sensations in the legs and an urge to move them. In Spain, its prevalence range is estimated to be between 11.6% - 19.5% in adults, but it is difficult to know due to underdiagnosis. Alpha-lipoic acid (ALA) and B vitamins have emerged as potential treatments due to their roles in reducing oxidative stress and associated vitamin deficiencies. The Tiobec® 400 (T400) supplement combines ALA, B vitamins, E, and C, and its efficacy and safety in alleviating RLS symptoms, along with its impact on anthropometric measures, are under investigation. This study aims to explore therapeutic options for managing RLS, with promising results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Restless Legs Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alpha-lipoic acid combined with B vitamins

The investigational product utilized in this research, Tiobec® 400 is a dietary supplement enriched with ALA, B vitamins, and vitamins E and C. T400 is designed to mitigate oxidative stress and support the optimal functioning of the nervous system

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be a minimum of 18 years of age.
* They must have a primary diagnosis of RLS without prior therapeutic interventions for the ailment.
* They need to provide explicit consent via an informed consent document.

Exclusion Criteria

* Patients diagnosed with pathologies other than RLS that affect sleep quality.
* Those with persistent renal diseases or any other chronic, severe medical condition.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No